Results 121 to 130 of about 53,892 (275)

A rare case of breast carcinoma co-existing with axillary mantle cell lymphoma

open access: yesWorld Journal of Surgical Oncology, 2003
Background Mantle cell lymphoma (MCL) is a rare variety of non-Hodgkin's lymphoma which originates from CD5+ B-cell population in the mantle zones of lymphoid follicles. Coexistence of such tumours in the axillary lymph nodes with invasive breast cancers
Scally John   +3 more
doaj   +1 more source

A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma [PDF]

open access: bronze, 2020
Hun Ju Lee   +5 more
openalex   +1 more source

Telomere protein complexes and their role in lymphoid malignancies [PDF]

open access: yes, 2017
Telomeres are highly regulated and dynamic complexes that protect the genomic DNA and prevent the end of linear chromosomes from being misrecognized as a broken DNA.
Dos Santos, Patricia Carolina   +2 more
core  

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 149-158, January 2026.
Summary A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 ...
Swetha Kambhampati Thiruvengadam   +11 more
wiley   +1 more source

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas [PDF]

open access: yes, 2007
Integrative genomic and gene-expression analyses have identified amplified oncogenes in B-cell non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor suppressor genes within homozygous deletions remains unexplored.
Agirre-Ena, X. (Xabier)   +20 more
core  

Artificial intelligence for risk assessment and outcome prediction in malignant haematology

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 25-38, January 2026.
Machine learning models allow for dynamic and scalable risk stratification and outcome prediction. Different modalities of data such as electronic health records, patient genetics or laboratory results can be used as input. ML models autonomously select features weighing their prognostic value. Methods of model explainability in feature selection allow
Jan‐Niklas Eckardt   +3 more
wiley   +1 more source

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). [PDF]

open access: yes, 2019
Angioimmunoblastic T-cell lymphoma (AITL) is one of four major subtypes of nodal peripheral T cell lymphoma, characterized by its cell of origin, the follicular helper T-cell (TFH).
Alpdogan, Onder   +7 more
core   +1 more source

Role of Frailty in Assessing Eligibility for CAR T‐Cell Therapy in Haematology

open access: yesEuropean Journal of Haematology, Volume 116, Issue 1, Page 4-13, January 2026.
ABSTRACT Background and Objectives Frailty is a key consideration in determining whether a patient is robust enough for CAR T‐cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T‐cell therapy ...
Jennifer Clesham   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy